Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01490866 · ClinicalTrials.gov registry record · Phase 2
A Trial of Single Agent Axitinib as Maintenance Therapy for Patients With First Line Metastatic Colorectal Cancer (mCRC)
A Phase 2 study of Colorectal Cancer, sponsored by SCRI Development Innovations.
- Completed
- Registry status
- Phase 2
- Development phase
- 70
- Enrollment target
- 12
- Study locations
NCT01490866: Completed Phase 2 study of Colorectal Cancer, sponsored by SCRI Development Innovations.
NCT01490866 is a Phase 2 study of Colorectal Cancer that has completed, run by SCRI Development Innovations. The registered enrollment target is 70 participants, below the 1,544-participant average among 381 other Colorectal Cancer trials with a reported enrollment target (95% lower). The trial reports 12 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01490866, a Phase 2 study of Colorectal Cancer, has completed, sponsored by SCRI Development Innovations.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 70 participants
- Enrollment target
- 12
- Study locations
Study Summary
This is a non-randomized, open-label, Phase II trial investigating axitinib as a single-agent maintenance therapy following standard first-line FOLFOX/bevacizumab therapy for patients with mCRC.
Primary Outcome
Defined as the time from first treatment until objective tumor progression or death from any cause, assessed according to Response Evaluation Criteria for Solid Tumors (RECIST) v1.1.
Conditions Studied
Interventions
- DRUG Bevacizumab
- DRUG Leucovorin
- DRUG 5-Fluorouracil
- DRUG Axitinib
Study Locations (12)
Florida
- Florida Cancer Specialists-South - Fort Myers
- Woodlands Medical Specialists - Pensacola
- Florida Cancer Specialists-North - St. Petersburg
Indiana
- Oncology Hematology of SW Indiana - Newburgh
- Hope Cancer Center - Terre Haute
Arkansas
- NEA Baptist Clinic - Jonesboro
Georgia
- Northeast Georgia Medical Center - Gainesville
Michigan
- Grand Rapids Oncology Program - Grand Rapids
Nebraska
- Nebraska Methodist Hospital - Omaha
New Jersey
- Atlantic Health System - Summit
Tennessee
- Tennessee Oncology - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2012-01 |
| Est. Completion | 2015-07 |
| Phase | Phase 2 |
What the finished NCT01490866 record still lists
NCT01490866 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 70 participants, a relatively small participant target, below the 1,544-participant average among 381 other Colorectal Cancer trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Colorectal Cancer appearing as the primary indexed condition, and to 4 interventions - of which Bevacizumab is the first listed.
NCT01490866 lists 12 locations in 9 states (Florida, Indiana, Arkansas).
Frequently Asked Questions
What is clinical trial NCT01490866 about?
NCT01490866 is a clinical study titled "A Trial of Single Agent Axitinib as Maintenance Therapy for Patients With First Line Metastatic Colorectal Cancer (mCRC)". This is a non-randomized, open-label, Phase II trial investigating axitinib as a single-agent maintenance therapy following standard first-line FOLFOX/bevacizumab therapy for patients with mCRC.
What is the current status of trial NCT01490866?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 70 participants. The study started on 2012-01. Estimated completion is 2015-07.
What conditions does trial NCT01490866 study?
This clinical trial studies the following conditions: Colorectal Cancer.
What interventions are being tested in trial NCT01490866?
The interventions under investigation include: Bevacizumab (DRUG), Leucovorin (DRUG), 5-Fluorouracil (DRUG), Axitinib (DRUG).
Who is sponsoring clinical trial NCT01490866?
This trial is sponsored by SCRI Development Innovations, which has 146 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01490866 being conducted?
This trial has 12 study locations across Arkansas, Florida, Georgia, Indiana, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colorectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01490866's enrollment target sits among peer trials
70 244th of 381 higher than 134 of 381 other Colorectal Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Colorectal Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease
RECRUITING · Phase 2
-
A Study of Single Fraction Stereotactic Body Radiation Therapy (SBRT) Guided by Magnetic Resonance Imaging (MRI) in People With Liver Metastasis From Colorectal Cancer
RECRUITING · Phase 2
-
TAS-102 With or Without Celecoxib in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy
RECRUITING · Phase 2
-
A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy
RECRUITING · Phase 2
-
A Study of IBI363 in Subjects with Advanced Solid Malignancies
RECRUITING · Phase 2
-
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00969111 · 70 participants · NA
Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy
- NCT01712620 · 70 participants · Phase 2
Spironolactone for Pulmonary Arterial Hypertension
- NCT02143830 · 70 participants · Phase 2
HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
- NCT02601339 · 70 participants
NIRS Monitoring in Premature Infants
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia